Clinical Trial Update: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab [Phase 3]

View source ↗

Summary

Phase 3 trial in metastatic colorectal cancer (RAS-wildtype) after response to first-line FOLFIR plus cetuximab has completed; the update notes the trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED